Current Fungal Infection Reports

, Volume 5, Issue 2, pp 57–58

Optimizing Amphotericin B Therapy for Cryptococcal Meningitis

Clinical Trial Report


  1. 1.
    Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992–2000. Clin Infect Dis. 2003;36:789–94.PubMedCrossRefGoogle Scholar
  2. 2.
    Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291–322.PubMedCrossRefGoogle Scholar
  3. 3.
    van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997;337:15–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Klepser ME, Wolfe EJ, Pfaller MA. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. J Antimicrob Chemother. 1998;41:397–401.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Ferris State University College of PharmacyKalamazooUSA

Personalised recommendations